Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 9/20 | 0.38 |
| ▸ | NOS2 | P35228 | 9/20 | 0.38 |
| ▸ | NOS1 | P29475 | 8/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22251108 | 0.77 | SMN1; SMN2 (0.50) | POLBALDH1A1 | |
| SCHEMBL26705124 | 0.77 | ALDH1A1 (0.39) | POLBALDH1A1 | |
| SCHEMBL3637109 | 0.77 | NOS3 (0.41) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL21287270 | 0.77 | NOS3 (0.41) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL21730240 | 0.74 | NOS3 (0.38) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL30915338 | 0.74 | NOS3 (0.38) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL21223482 | 0.74 | NOS3 (0.38) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL22028956 | 0.74 | HSP90AA1 (0.36) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL29936752 | 0.74 | HSP90AA1 (0.36) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL27051415 | 0.71 | NOS2 (0.42) | NOS3NOS2NOS1BACE1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059163-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4483881-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| EP-3735299-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-10-02 | — | — | EP | disclosed |
| US-12084429-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-118084867-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084870-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084866-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084868-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112105419-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230089126-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-11236068-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210230142-A9 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-29 | — | — | US | disclosed |
| CN-112105419-A | Fused ring compound | 豪夫迈·罗氏有限公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3735299-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-11-11 | — | — | EP | disclosed |
| US-20200181118-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230142-A9 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | NOS3 3408/4885NOS2 3039/4885NOS1 3354/4885 |
| US-20230089126-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | NOS3 3408/4885NOS2 3039/4885NOS1 3354/4885 |
| US-12084429-B2 | Fused ring compounds | KRAS, NRAS, HRAS | NOS3 3408/4885NOS2 3039/4885NOS1 3354/4885 |
| US-20250059163-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | NOS3 3408/4885NOS2 3039/4885NOS1 3354/4885 |
| US-20200181118-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | NOS3 3408/4885NOS2 3039/4885NOS1 3354/4885 |
| US-11236068-B2 | Fused ring compounds | KRAS, NRAS, HRAS | NOS3 3408/4885NOS2 3039/4885NOS1 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.